YHYulun Huang

Yulun Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yulun Huang has a total of 244 co-authors. Here are the top co-authors by number of shared publications:

  • Xuetao Li

    Department of Neurosurgery The Fourth Affiliated Hospital of Soochow University Suzhou China

    11 shared publications
  • Xuewen Zhang

    The Fourth Affiliated Hospital of Soochow University Suzhou China

    9 shared publications
  • Jiangang Liu

    Department of Neurosurgery, The First Affiliated Hospital of SooChow University, Suzhou, China

    8 shared publications
  • Yang Zhang

    Department of Neurosurgery The Fourth Affiliated Hospital of Soochow University Suzhou China

    8 shared publications
  • Haiping Zhu

    Department of Neurosurgery The Fourth Affiliated Hospital of Soochow University Suzhou China

    6 shared publications
  • Hui Yao

    Department of Neurosurgery, The First Affiliated Hospital of SooChow University, Suzhou, China

    6 shared publications

Latest Publications

  • Open Access

    An Integrated Paradigm for Brainstem Cavernoma Surgery : Combining Defined Surgical Timing with Diffusion Tensor Imaging-Guided Tractography

    by Liang He, Zongyu Xiao, Ke Xu, Zhengyang Lu, Chenlong Wang, Yulun Huang

    Objective : To evaluate a surgical strategy for hemorrhagic brainstem cavernous malformations by assessing 1) the impact of surgical timing (hemorrhage-to-surgery interval), and 2) the utility of preoperative diffusion tensor imaging (DTI) tractography for corticospinal tract (CST) preservation.Methods : In a retrospective cohort of 41 consecutive patients, the hemorrhage-to-surgery interval was stratified into acute (8 weeks). Preoperative DTI tractography for CST mapping was utilized in 24 patients (DTI group) and not in 17 (non-DTI group); assignment was determined by magnetic resonance imaging scanner availability rather than clinical selection. The primary outcome was unfavorable functional status (modified Rankin scale score >2) at final follow-up.Results : The median hemorrhage-to-surgery interval was 53.0 days. Delayed surgery independently predicted unfavorable outcome at discharge (adjusted odds ratio, 9.03; 95% confidence interval, 1.10–73.94; p=0.04). Preoperative DTI was associated with a significantly lower rate of postoperative motor deterioration at discharge (12.5% vs. 47.1%; p=0.04). Subgroup analysis showed that the protective effect of DTI was significant only in the delayed surgery group (p=0.04), whereas among patients operated within 8 weeks, motor deterioration rates were low regardless of DTI use (16.7% vs. 16.7%; p=1.00). Persistent postoperative motor deficit was the strongest determinant of long-term disability (44.4% vs. 3.1%; p=0.006).Conclusion : A hemorrhage-to-surgery interval exceeding 8 weeks independently predicts poorer early functional recovery. Preoperative DTI tractography reduces postoperative motor deficits—the key driver of long-term disability—with its benefit most pronounced in the delayed surgery setting. We propose a risk-stratified, dual-emphasis strategy : timely intervention within 8 weeks when feasible, complemented by DTI tractography, which is particularly valuable in mitigating the increased risks of delayed surgery. This framework offers a practical, evidence-informed approach for optimizing functional outcomes.


  • Open Access

    Tumor Treating Fields Enhance Temozolomide‐Associated Growth Suppression in Glioblastoma Cells and Patient‐Derived Organoids Through Cell‐Cycle Blockade, Apoptosis, and SMAD ‐Associated Signaling

    by Haiping Zhu, Yingbo Hou, Xuetao Li, Yi Tang, Zuoyu Jiang, Yang Zhang, Xuewen Zhang, Jiaming Du, Yang Zhu, Hanmiao Dong, et al.

    Aims: Glioblastoma (GBM) remains difficult to treat despite multimodal therapy. Tumor Treating Fields (TTF) disrupts mitosis and provides clinical benefit in GBM, but the molecular responses associated with TTF and the effects of combining TTF with temozolomide (TMZ) remain incompletely defined. Methods: TMZ, TTF, and TMZ + TTF were evaluated in U251 and SHG140 GBM cells and patient‐derived organoids. TTF was applied at 200 kHz and 1.75 V/cm RMS. Viability, colony formation, migration‐related phenotypes, apoptosis, cell‐cycle distribution, Western blotting, qRT‐PCR, RNA‐seq, and organoid morphology/immunofluorescence analyses were performed. SB525334 was used to assess SMAD‐associated signaling. Results: Combined TMZ + TTF treatment more strongly suppressed cell viability, clonogenic growth, and migration‐related phenotypes than either monotherapy, produced greater disruption of organoid structural integrity, and was accompanied by increased cleaved caspase‐3 activation and apoptotic populations. RNA‐seq identified TTF‐associated transcriptomic changes involving chromatin‐associated processes, DNA replication, and cell‐cycle pathways. TTF was associated with selected SMAD‐related signaling changes, G2/M accumulation, altered checkpoint signaling, and enhanced proapoptotic signaling. SB525334 partially attenuated TTF‐associated SMAD phosphorylation, growth suppression, and cleaved caspase‐3 induction. Conclusion: TTF enhances TMZ‐associated antitumor responses in GBM cell lines and organoids, accompanied by cell‐cycle blockade, apoptosis‐associated changes, and selected SMAD‐related signaling responses.

  • Open Access

    Stent-assisted coiling for ruptured anterior choroidal artery aneurysms

    by Liang He, Weiwei Zhu, Yang Liu, Yulun Huang

    Aneurysms of the anterior choroidal artery (AChA) are rare and pose treatment challenges due to eloquent adjacent anatomy and often complex morphology. This retrospective study evaluates the safety and efficacy of endovascular treatment, particularly stent-assisted coiling (SAC), for acutely ruptured AChA aneurysms, focusing on complications and antiplatelet management. We retrospectively analyzed 29 consecutive patients treated endovascularly within 72 hours of ictus. Patients were stratified by technique (coiling alone, n = 11 vs SAC, n = 18). Within the SAC cohort, 2 antiplatelet regimens were compared: dual antiplatelet therapy (DAPT, n = 7) versus intravenous tirofiban (n = 11). The primary outcome was a favorable clinical outcome (modified Rankin Scale: 0–2) at 6 months. No procedure-related mortality occurred. Periprocedural complication rates were comparable between groups (all P > .05). The overall rate of ischemic events (including intraoperative thrombosis and symptomatic infarction) was 27.8% (5/18) in the SAC group and 9.1% (1/11) in the coiling-alone group. Favorable clinical outcomes at 6 months were achieved in 90.9% of the coiling-alone group and 88.9% of the SAC group (discharge: 72.7% vs 77.8%). After inverse probability of treatment weighting adjustment, SAC was associated with an odds ratio of 1.13 (95% confidence interval [CI]: 0.14–9.09) for favorable outcome. The absolute risk reduction for recurrence was 27.3% (95% CI: 1.0%–53.6%), corresponding to number needed to treat = 3.7 (95% CI: 2.1–14.9). SAC demonstrated a trend toward higher complete occlusion (88.9% vs 63.6%; P = .16) and lower recurrence (0% vs 27.3%; P = .045; fragility index = 1). Within the SAC subgroup, no significant differences were observed between DAPT and tirofiban. Endovascular treatment, particularly SAC, appears to be a safe and feasible option for ruptured AChA aneurysms, with the potential for durable occlusion. However, given the small sample size and exploratory nature of this study, these findings should be considered hypothesis-generating and require confirmation in larger prospective cohorts. Both DAPT and tirofiban appear to be feasible antiplatelet strategies based on the limited data available.

  • Open Access

    Dorsum sellae meningioma resected via mini-combined transpetrosal approach: illustrative case

    by Verónica de Los Santos, Zongyu Xiao, Arianna Fava, Haiping Zhu, Thibault Passeri, Yulun Huang, Sebastien Froelich

    BACKGROUND: Meningiomas arising from the dorsum sellae and upper clival region are extremely rare and pose significant surgical challenges due to their deep midline location and intimate relationships with critical neurovascular structures. Optimal surgical management remains controversial. OBSERVATIONS: The authors present the case of a 66-year-old woman with progressive bilateral visual loss secondary to a large dorsum sellae meningioma. The tumor was resected through a single-stage mini-combined transpetrosal approach. This approach enabled early devascularization, clear visualization of neurovascular anatomy, and preservation of critical structures. The patient had a favorable postoperative course without complications. LESSONS: The mini-combined transpetrosal approach provides a versatile and effective surgical corridor for tumors of this region. Careful preoperative planning and detailed knowledge of microsurgical anatomy are essential to maximize tumor removal and minimize morbidity. https://thejns.org/doi/10.3171/CASE25839

  • Open Access

    NeuroD1 gene therapy inhibits glioma growth and extends life span through in vivo reprogramming approach

    by Yuchen Chen, Zuoyu Jiang, Sen Jin, Meng Liu, Ming Chen, Tsang-Chih Kuo, Kai Zhou, Liting Pu, Shiyuan Chen, Xuetao Li, et al.

  • Open Access

    TGF ‐β Blockade With SB525334 Enhances B7 ‐ H3 CAR ‐ γδT Cell Efficacy Against Glioblastoma

    by Yang Zhu, Zijian Han, Zijing Zhou, Yinqiang Sui, Yang Zhang, Zuoyu Jiang, Qinzhi E, Xuewen Zhang, Weichao Wang, Yingbo Hou, et al.

    Transforming growth factor‐beta (TGF‐β) signalling promotes glioblastoma (GBM) immunosuppression and therapy resistance. Although CAR‐γδT therapy has shown promising efficacy in hematologic malignancies, its application to solid tumours—particularly GBM—is impeded by multiple factors, including a highly immunosuppressive tumour microenvironment, inefficient T‐cell infiltration, T‐cell exhaustion driven by inhibitory pathways such as TGF‐β, and antigen heterogeneity. Bioinformatics analyses further corroborate that TGFB1 is significantly upregulated in GBM and correlates with poor prognosis, highlighting TGF‐β as a pivotal mediator of therapeutic resistance. This study aimed to evaluate whether SB525334, a selective TGF‐β receptor inhibitor, can enhance the efficacy and persistence of CAR‐γδT cells in GBM. We demonstrate that SB525334 selectively enhances CAR‐γδT cell function and antitumour efficacy by alleviating TGF‐β–mediated immunosuppression and T‐cell exhaustion while promoting immune activation within the GBM microenvironment. The combination treatment significantly reduced tumour cell viability (approximately 40%–50% residual viability) compared to CAR‐γδT therapy alone (70%–85% residual viability), indicating a clear synergistic effect. Unlike broad‐spectrum inhibitors, SB525334 sustains CAR‐γδT proliferative capacity and effector function under chronic antigen stimulation, remodels the immunosuppressive tumour microenvironment, and promotes a pro‐inflammatory immune signature. Our findings establish a combination strategy to overcome immunosuppressive barriers that limit current CAR‐γδT therapies in solid tumours. By maintaining T‐cell function and remodelling the tumour immune microenvironment, TGF‐β1 small‐molecule inhibitors show potential as translational adjuvants to broaden the clinical applicability of CAR‐γδT cell immunotherapy.

  • Open Access

    Spinal high-grade astrocytoma with piloid features arising in a patient with molecularly confirmed cerebellar pilocytic astrocytoma

    by Xiaoci Rong, Nan Chen, Yanghao Hou, Haiping Zhu, Xuetao Li, Jie Shao, Sujuan Zhou, Dongbing Li, Yun Ning, Wenjuan Gan, et al.

    Pilocytic astrocytoma (PA) is a benign tumor with a low risk of high-grade transformation. High-grade astrocytoma with piloid features (HGAP) is a recently recognized tumor entity that may arise de novo or from low-grade gliomas. Here, we report a patient harboring both a fourth ventricular PA and a spinal cord tumor. Methylation profiling classified the brain tumor as PA and the spinal tumor as HGAP. Both tumors shared a KIAA1549::BRAF fusion with identical DNA breakpoints, confirming a common clonal origin. The spinal tumor also showed complex chromosome copy number aberrations, including homozygous deletion of CDKN2A/B. These findings suggest additional molecular alterations associated with tumor progression within the piloid lineage. To our knowledge, this is the first report providing comprehensive, paired molecular characterization of both PA and HGAP in the same patient, offering insight into their potential evolutionary relationship.

  • Top Cited Papers
    Open Access

    Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation

    by Yi Tang, Qinzhi E, Liang Ma, Xuetao Li, Yang Zhang, Weichao Wang, Zuoyu Jiang, Xuewen Zhang, Yingbo Hou, Jiaming Du, et al.

    Glioblastoma (GBM) remains therapeutically challenging due to treatment resistance and immunosuppression. Oncolytic virotherapy offers a promising strategy. This study engineered OVV-03, a novel HER2-armed oncolytic vesicular stomatitis virus (VSV), and evaluated its efficacy against GBM. OVV-03 demonstrated potent infectivity and cytotoxicity in GBM cell lines and patient-derived cells, inducing caspase-dependent apoptosis and suppressing proliferation/clonogenicity. In murine GBM models, OVV-03 significantly suppressed tumor growth, improved survival, and enhanced CD8⁺ T cell infiltration. Single-cell RNA sequencing revealed OVV-03 remodels the tumor immune microenvironment by boosting cytotoxic T cell activity and inhibiting immunosuppressive pathways, notably PD-L1/PD-1 signaling. Mechanistically, OVV-03 downregulated PD-L1 by inhibiting the JNK-c-Fos/c-Jun axis, reversible by TNF-α stimulation. Critically, OVV-03 synergized with B7H3- or HER2-targeted CAR-T cells, inducing superior tumor regression and prolonged survival in orthotopic models. These findings demonstrate that OVV-03 exerts potent antitumor effects through direct oncolysis and immune activation, including PD-L1 modulation. Its synergistic combination with CAR-T cells highlights OVV-03 as a highly promising oncolytic immunovirotherapy platform for GBM.


  • Open Access

    Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial

    by Xuetao Li, Xiaoyun Shang, Jiangang Liu, Yang Zhang, Xian Jia, Huabing Li, Yihan Wang, Jianen Gao, Xu Ma, Xuewen Zhang, et al.

    Patients with recurrent high-grade glioblastoma have a median survival of 6-8 months, with limited therapeutic options. In recent years, interest has grown in applying chimeric antigen receptor T (CAR-T) cells to solid cancers, including advanced gliomas. Here we generated off-the-shelf CRISPR-Cas9–edited IL-13Rα2-specific allogeneic universal CAR-T cells (MT026) by disrupting the endogenous TCR to prevent graft-versus-host disease and knocking out HLA class I molecules to mitigate the host-versus-graft response, and observed minimal NK-cell–mediated rejection in preclinical studies. In a first-in-human, single-center, open-label investigator-initiated trial (ChiCTR2000028801) in patients with high-grade glioma with prior therapy failure and short life expectancy, intrathecal injection of MT026 via lumbar puncture (1.0-3.0×10^7 cells per dose) demonstrated favorable tolerability and safety (primary outcome), pharmacokinetic characteristics, and preliminary clinical activity (secondary outcomes). Among the five patients enrolled, one achieved a complete response and three achieved partial responses. No grade ≥3 adverse events were observed; the predominant treatment-related toxicities were grade 1-2 pyrexia, hypoxia, and vomiting. Trial enrolment was halted after enrolment of the first five patients, however these preliminary clinical data support the potential benefit of locally administered allogeneic universal CAR-T cell therapy for recurrent glioblastoma.